Clinical trials: Psoriasis Patients
Moderate to Severe Plaque Psoriasis
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT02607774
- Testing
- Midazolam, AIN457
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Periodontal Diseases, Psoriasis
Periodontal Status in Patients With Chronic Skin Diseases
Objective: This study aimed to evaluate and compare the periodontal status of chronic skin disease (CSD) patients with healthy controls. Material and method: 109 patients and 37 healthy subjects were included in this study.
- Conditions
- Periodontal Diseases, Psoriasis, Atopic Dermatitis, Autoimmune Bullous Dermatosis
- Trial name
- NCT06073613
- Testing
- oral health status
- Where
- Vietnam
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Nail Psoriasis
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
The aim of this study is to determine the efficacy and safety of topical application of the gel compared to placebo in nail psoriasis.
- Trial name
- NCT02235480
- Testing
- Experimental Tazarotene Gel
- Where
- 4 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Almirall, S.A.
Psoriasis
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01276639
- Testing
- CP-690,550
- Where
- 74 sites in United States, Canada and 9 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
- Trial name
- UNCOVER-3 (NCT01646177)
- Testing
- 50 mg etanercept, 80 mg ixekizumab
- Where
- 101 sites in United States, Argentina and 8 more
- Volunteers
- 1,346 people
- Sponsor
- Eli Lilly and Company
Psoriasis Chronic, Liver Fibrosis
An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
Main objectives and outcome measures. 1. Establish prevalence of and factors contributing to fatty liver disease and liver fibrosis in patients with psoriasis. Fatty liver disease diagnosed via ultrasound.
- Conditions
- Psoriasis Chronic, Liver Fibrosis, Fatty Liver, Non-alcoholic Fatty Liver Disease
- Trial name
- CORE (NCT02174367)
- Testing
- Transient elastography
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- King's College London
Psoriasis
A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis
- Trial name
- NCT01045577
- Testing
- Masitinib
- Volunteers
- 25 people
- Sponsor
- AB Science
Psoriasis, Psoriasis Arthritis
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
The inclusion criteria for this study were patients aged 18 to 75 years with a confirmed diagnosis of psoriasis by a dermatologist or psoriatic arthritis by a rheumatologist.
- Conditions
- Psoriasis, Psoriasis Arthritis, Biologics
- Trial name
- SMILE (NCT07149792)
- Testing
- Prescreen platform, biologics treatment
- Where
- 2 sites in Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Plaque Psoriasis
Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis
The main objective of the study is to evaluate the additional effect of a narrow band Type B Ultraviolet (UVB) therapy on the treatment of severe plaque psoriasis with fumaric acid esters (FAE) in comparison to FAE monotherapy.
- Trial name
- NCT01321164
- Testing
- Full Body UV Therapy System UV 7002 plus fumaric acid esters, Fumaric acid esters
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Psoriasis, Psoriatic Arthritis
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients
Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients' quality of life enormously. Psoriasis refers to a persistent inflammatory illness of the skin and joints.
- Trial name
- NCT06729463
- Testing
- Humira
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- South Valley University
Plaque Psoriasis
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in…
- Trial name
- NCT05650060
- Testing
- Secukinumab
- Where
- Thailand
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris, Rheumatoid Arthritis
Liver Fibrosis and Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate
While methotrexate (MTX) remains a treatment of choice for patients with rheumatoid arthritis (RA), psoriasis (PsO) and psoriatic arthritis (PsA), long-term MTX use has been shown to be associated with liver fibrosis and…
- Conditions
- Psoriasis Vulgaris, Rheumatoid Arthritis, Fibrosis, Liver
- Trial name
- NCT04493762
- Volunteers
- 600 people
- Sponsor
- The University of Hong Kong
Psoriasis
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and…
- Trial name
- UNMASK2 (NCT04894890)
- Testing
- secukinumab
- Where
- 42 sites in China
- Volunteers
- 1,002 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque…
- Trial name
- NCT05442788
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriatic Arthritis
Changes in Body Composition Under Ustekinumab in PsA
There is not much body composition and bone mineral density data available for patients with psoriatic arthritis (rheumatoid arthritis) compared to control subjects.
- Trial name
- STELARA-CC (NCT03823924)
- Testing
- Bone mineral density (BMD)
- Where
- France
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Psoriasis
Effect of Sublimated Mare Milk Supplement on Gut Microbiome in Psoriasis Patients
This study evaluates the effect of dietary supplement consisting of sublimated mare milk on intestinal microbiota among psoriasis and healthy participants.
- Trial name
- NCT03594877
- Testing
- Sublimated mare milk
- Where
- Kazakhstan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nazarbayev University Medical Center
Plaque Psoriasis
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
This study seeks to show whether there is a benefit of prescribing Enstilar in the treatment of patients with moderate plaque type psoriasis. Subjects will receive study treatment of Enstilar foam.
- Trial name
- NCT03848871
- Testing
- Enstilar
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Psoriatic Arthritis
Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
This study is designed as a proof of concept of AIN457 in patients with psoriatic arthritis. The study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of AIN457 10 mg/kg administered three…
- Trial name
- NCT00809614
- Testing
- AIN457
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Generalized Pustular Psoriasis
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo.
- Trial name
- NCT07314060
- Testing
- TQH2929 Injections
- Where
- 31 sites in China
- Volunteers
- 36 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.